Analysis reveals combined APE1 and STAT3 inhibition reduces cell viability in breast cancer, suggesting new treatment targets.
Aggressiveness and resistance to treatments are significant problems in cancer management. In this scenario, searching for new pharmacological targets for therapies is essential. The APE1 redox domain coactivates transcription factors that favor cancer malignancy. One of APE1's targets, STAT3, coordinates the transcription of genes involved in cancer hallmarks. However, the association between APE1 and STAT3 in the context of breast cancer cell survival and aggressiveness has not been previously characterized. Therefore, we investigated the role of the redox function of APE1 and STAT3 inhibitors in cell viability, proliferation, migration, invasion, and cell death. In addition, we verified the association between APE1 and STAT3 in breast cancer patient samples from TCGA and their relationship with proliferation and metastasis. Our results suggest that combined treatment with APE1 and STAT3 inhibitors can further synergistically reduce cell viability, proliferation, migration, and invasion, compared to treatment with inhibitors alone. Moreover, the APE1 and STAT3 activity levels positively correlated with proliferation and metastasis gene signatures. Thus, we suggest the APE1 redox domain and STAT3 as promising targets for new therapy strategies against breast cancer.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: